NextCell Pharma AB (NXTCL.ST)
NextCell Pharma AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Huddinge, AB, SE. The stock last traded at $1.02, up 0.59% on the session, giving a market capitalisation of $113.4M. Its beta of 0.72 implies it has historically moved less than the broad market.
NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.
NextCell Pharma AB is most often compared with the following Healthcare names: